Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2021-07-20 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-07-20 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer, signed by the President and CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2021. The text is primarily a certification letter without actual financial data or detailed financial statements. It references an interim report but does not contain the report itself. The document length is short (3061 characters), and it fits the criteria of an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR).
2021-06-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate' signed by the Interim CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2021. The content is primarily an officer certification regarding the interim filings, not the filings themselves. It explicitly states it is a certification and does not contain actual financial data or substantive financial analysis. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR). The document length is short (3099 characters), consistent with a certification letter rather than a full report.
2021-06-30 English
52-109FV2 - Certification of interim filings - CFO (F).pdf
Regulatory Filings Classification · 95% confidence The document is an attestation by the interim CFO regarding the review of the interim financial report and management report for the period ended April 30, 2021. It explicitly states it is an attestation for an emerging issuer under Canadian regulation 52-109, focusing on the accuracy and fair presentation of the interim financial documents. The document does not contain the actual financial statements or substantive financial data but is a certification letter about those reports. According to the Certification Rule, such attestations should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3651 characters, which is relatively short and consistent with a certification letter rather than a full report.
2021-06-30 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 95% confidence The document is an attestation by the CEO regarding the interim financial report and management report for the period ended April 30, 2021. It explicitly states it is an attestation for an emerging issuer under Canadian regulation 52-109. The document does not contain actual financial statements or substantive financial data but is a certification of the interim documents. According to the Certification Rule, such attestations or officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is 3625 characters, which is relatively short and consistent with a certification rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2021-06-30 English
Interim MD&A - French.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "RAPPORT DE GESTION – POUR LE TRIMESTRE TERMINÉ LE 30 AVRIL 2021" which translates to "Management Report for the quarter ended April 30, 2021." It contains detailed discussion of the company's activities, financial situation, clinical study results, and financial performance for the quarter and nine months ended April 30, 2021. It includes substantive financial data such as net loss figures, revenue, and operational highlights. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. Q3 2021
2021-06-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.